David Shaw’s Fresh Tracks Therapeutics, Inc. Common Stock FRTX Stock Holding History

David Shaw’s Portfolio FRTX Stock Details FRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q2	–	Sell	-158	Closed	-$470K	–	3912
2015 Q1	$470K	Sell	158 -1	-0.6%	-$3.2K	﹤0.01%	3084
2014 Q4	$526K	Sell	159 -24	-13%	-$85K	﹤0.01%	3287
2014 Q3	$646K	Sell	183 -139	-43%	-$540K	﹤0.01%	3150
2014 Q2	$1.24M	Sell	322 -10	-3%	-$37.6K	﹤0.01%	2739
2014 Q1	$1.35M	Buy	332 +318	+2,271%	+$1.42M	﹤0.01%	2774
2013 Q4	$53K	Buy	+14	New	+$53K	﹤0.01%	4393
2013 Q3	–	Sell	-4	Closed	-$42K	–	4504
2013 Q2	$42K	Buy	+4	New	+$44.3K	﹤0.01%	3925

Other funds holding FRTX

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Ariel Investments Chicago, Illinois $10B AUM 42.59% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.26% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

RSCM

Rock Springs Capital Management Baltimore, Maryland $2.05B AUM 161.37% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

New York State Common Retirement Fund Albany, New York $79.3B AUM 43.63% 1-Year Est. Return

SGAM

Smith Group Asset Management Dallas, Texas $2.46B AUM 57.16% 1-Year Est. Return

Jacobs Levy Equity Management Florham Park, New Jersey $27.8B AUM 46.46% 1-Year Est. Return

David Shaw's FRTX Position: Q2 2015 in Review

David Shaw sold out of Fresh Tracks Therapeutics, Inc. Common Stock (FRTX) in Q2 2015, closing a stake of 158 shares — an estimated $470K sold.

David Shaw first reported a position in FRTX in Q2 2013 and held it in 7 quarters. The position peaked at $1.35M in Q1 2014. 58 funds tracked by Wall St. Rank hold FRTX as of Q2 2015.

David Shaw reported no remaining Fresh Tracks Therapeutics, Inc. Common Stock position as of Q2 2015 after selling out during the quarter.
David Shaw sold 158 Fresh Tracks Therapeutics, Inc. Common Stock shares in Q2 2015, an estimated $470K.
David Shaw first reported a position in Fresh Tracks Therapeutics, Inc. Common Stock in Q2 2013 and held it in 7 quarters.
David Shaw's Fresh Tracks Therapeutics, Inc. Common Stock position peaked at $1.35M in Q1 2014.
58 funds tracked by Wall St. Rank held Fresh Tracks Therapeutics, Inc. Common Stock as of Q2 2015.

Based on D.E. Shaw & Co's 13F filing for Q2 2015, filed 14 Aug 2015.